| 日 | 月 | 火 | 水 | 木 | 金 | 土 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 |
< 抗CCP陽性RAとschizophren... | メイン | memo 手の外科 >
Susan Ott, MD Associate Professor Department of Medicine University of Washingtonのサイト？
http://courses.washington.edu/bonephys/oppregnancy.html#Bis
・ビスフォスホネート製剤治療を終了した婦人が妊娠した場合、理論的には胎児への影響が懸念される。すなわち、ビスフォスホネート製剤は骨基質に取り込まれ数週から数年の期間をかけて血中に放出される。従ってビスフォスホネート製剤中止後にどれくらいの量が骨から流血中に放出されるかは、薬剤の種類や総投与量（服用量Ｘ期間）に依存する。また、ヒトでの成績は少ないが、動物実験では胎児の骨は母体の骨よりもビスフォスホネートの取り込みが大きく、胎児がビスフォスホネート製剤の影響（骨格異常など）を受ける可能性はある。
・ビスフォスホネート製剤治療を終了した婦人がどのくらい待てば安全に妊娠できるかのデータは乏しいが、このサイトの著者は少なくとも１年間はあけるとアドバイスするという。
•Arthritis Research & Therapy 2006, 8(3):209：Anti-inflammatory and immunosuppressive drugs and reproductionのOsteoporosis preventionの項には、エキスパートの見解として、不十分なデーしかない現況では、ビスフォスホネート中止後六ヶ月間は妊娠しないようにと記載されている（レベルIV: a descriptive case series or an expert opinion.）
http://arthritis-research.com/content/8/3/209
"Because of insufficient data, pregnancy should be postponed for 6 months after withdrawal of bisphospho-nates (evidence level IV)".
コピーペースト
Women who are pregnant should not take bisphosphonates. If women are already taking a bisphosphonate and want to become pregnant, it is not clear how long they should wait. Until more information is available, I suggest waiting at least one year after stopping the medication to try getting pregnant.
If a woman is taking a bisphosphonate and inadvertantly gets pregnant and wants to continue the pregnancy, she should be carefully followed, with measurements of calcium and optimal vitamin D levels.
Calcitonin is a safe drug to use during pregnancy if bone loss is a concern. Young women should not be getting bisphosphonates anyway unless they definitely have established osteoporosis (that means they have non-traumatic fractures) and other methods are not working. Osteopenia in a healthy woman is not an indication for any bisphosphonate!
Bisphosphonates are incorporated into the bone matrix, from where they are gradually released over periods of weeks to years. The extent of bisphosphonate incorporation into adult bone, and hence, the amount available for release back into the systemic circulation, is directly related to the total dose and duration of bisphosphonate use. Although there are no data on fetal risk in humans, bisphosphonates do cause fetal harm in animals, and animal data suggest that uptake of bisphosphonates into fetal bone is greater than into maternal bone. Therefore, there is a theoretical risk of fetal harm (e.g., skeletal and other abnormalities) if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on this risk has not been established.
J Clin Endocrinol Metab. 2006 91(6):2017-20(Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases)にも少なくとも6-12ヶ月と記載されているようである。
She was advised to wait for at least 6–12 months before attempting a pregnancy, but conception occurred 3 months later. The pregnancy was uneventful apart from some back discomfort, with a normal vaginal delivery at 38 wk gestation of a ・・・・・
固定リンク | コメント (0) | トラックバック (0)
コメント
コメントはまだありません。コメントを書く